Clinical trial
Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or…
NCT00003462 · Duke University, Other · Completed
Key facts
| NCT number | NCT00003462 |
|---|---|
| Title | Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors |
| Official title | Phase I Study of Intrathecal Spartaject-Busulfan in Patients With Neoplastic Meningitis |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | busulfan |
| Enrollment | 20 |
| Start date | Apr 1, 1998 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: